Abstract
There has been great interest in transcatheter mitral valve replacement (TMVR) as a potential therapy for high-risk patients with severe mitral regurgitation, with several distinct device systems undergoing first-in-man clinical studies. The Intrepid TMVR (Medtronic Inc, Redwood City, CA), designed for transapical delivery, comprises 2 interconnected self-expanding nitinol stents: (1) an inner stent that houses a bovine pericardial tissue trileaflet valve and; (2) an outer ring that fixes to the mitral annulus by radial force in a cork-like effect (Figure 1).1 The outer fixation ring is designed to conform to the dynamic anatomy of the mitral valve throughout the cardiac cycle, avoiding distortion of the inner stent and valve. Figure 1. The Intrepid transcatheter mitral valve replacement with en face and side on views showing atrial brim, fixation …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
